Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump

J&J says Tylenol outpaced other analgesics in the first quarter as its OTC franchise grew 1.4% on a reported basis to $1.01 bn. CFO Dominic Caruso said new consumer products will add 2 points of incremental growth to the segment in 2017.